受体酪氨酸激酶抑制剂在恶性胶质瘤中的临床试验进展

摘要/Abstract

摘要：恶性胶质瘤的发生发展与受体酪氨酸激酶（RTK）过表达及其信号转导通路的异常激活密切相关，据此开发出的靶向治疗药物如RTK抑制剂、RTK下游信号通路抑制剂和多靶点抑制剂等能在分子水平上对恶性胶质瘤进行靶向性治疗，其中部分已通过临床试验，并取得良好疗效。

朱浩, 徐锦芳, 沈宏. 受体酪氨酸激酶抑制剂在恶性胶质瘤中的临床试验进展[J]. 国际肿瘤学杂志, 2013, 40(11): 833-836.

ZHU Hao, XU Jin-Fang, SHEN Hong. Clinical trials of receptor protein tyrosine kinase inhabitors in malignant glioma[J]. Journal of International Oncology, 2013, 40(11): 833-836.

［1］ McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008, 455(7216):1061-1068. ［2］ van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase Ⅱ trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol, 2009, 27(8):1268-1274. ［3］ Raizer JJ, Abrey LE, Lassman AB, et al. A phase Ⅰ trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy and recurrent malignant gliomas and meningiomas. J Neuro Oncol, 2010, 12(1):87-94. ［4］ Raizer JJ, Abrey LE, Lassman AB, et al. A phase Ⅱ trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. J Neuro Oncol, 2010, 12(1):95-103. ［5］ Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase Ⅱ trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. J Neuro Oncol, 2010,12(12):1300-1310. ［6］ Peereboom DM, Shepard DR, Ahluwalia MS, et al. Phase Ⅱ trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neuro Oncol, 2010, 98(1):93-99. ［7］ Chakravarti A, Wang M, Robins HI, et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys, 2013, 85(5):1206-1211. ［8］ Thiessen B, Stewart C, Tsao M, et al. A phase Ⅰ/Ⅱ trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol, 2010, 65(2):353-361. ［9］ Eskens FA, Mom CH, Planting AS, et al. A phase Ⅰ dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer, 2008, 98(1):80-85. ［10］ Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol, 2009, 5(11):610-620. ［11］ Brave SR, Ratcliffe K, Wilson Z, et al. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Mol Cancer Ther, 2011, 10(5):861-873. ［12］ Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell, 2007, 11(1):83-95. ［13］ Batchelor TT, Duda DG, di Tomaso E, et al. Phase Ⅱ study of cediranib, an oral panvascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol, 2010, 28(17):2817-2823. ［14］ Reardon DA, Egorin MJ, Desjardins A, et al. Phase Ⅰ pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer, 2009, 115(10):2188-2198. ［15］ Brandes AA, Stupp R, Hau P, et al. EORTC study 26041-22041: phase Ⅰ/Ⅱ study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer, 2010, 46(2):348-354. ［16］ Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol, 2010, 96(3):393-402. ［17］ Raymond E, Brandes AA, Dittrich C, et al. Phase Ⅱ study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol, 2008, 26(28):4659-4665. ［18］ Reardon DA, Dresemann G, Taillibert S, et al. Multicentre phase Ⅱ studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer, 2009, 101(12):1995-2004. ［19］ Minniti G, Muni R, Lanzetta G, et al. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res, 2009, 29(12):5171-5184. ［20］ Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a Phase Ⅰ trial for patients with recurrent PTENdeficient glioblastoma. PLoS Med, 2008, 5(1):e8. ［21］ Geoerger B, Kieran MW, Grupp S, et al. Phase Ⅱ trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer, 2012, 48(2):253-262. ［22］ Lassen U, Sorensen M, Gaziel TB, et al. Phase Ⅱ study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res, 2013, 33(4):1657-1660. ［23］ Lustig R, Mikkelsen T, Lesser G, et al. Phase Ⅱ preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol, 2008, 10(6):1004-1009. ［24］ Wick W, Puduvalli VK, Chamberlain MC, et al. Phase Ⅲ study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol, 2010, 28(7):1168-1174. ［25］ Lu KV, Zhu S, Cvrljevic A, et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res, 2009, 69(17):6889-6898. ［26］ Milano V, Piao Y, LaFortune T, et al. Dasatinibinduced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther, 2009, 8(2):394-406. ［27］ Iwamoto FM, Lamborn KR, Robins HI, et al. Phase Ⅱ trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol, 2010, 12(8):855-861. ［28］ Peereboom DM, Ahluwalia MS, Ye X, et al. NABTT 0502: a phase Ⅱ and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.Neuro Oncol, 2013, 15(4):490-496. ［29］ Pan E, Yu D, Yue B, et al. A prospective phase Ⅱ single-institution trial of sunitinib for recurrent malignant glioma.J Neurooncol, 2012, 110(1):111-118. ［30］ Kreisl TN, McNeill KA, Sul J, et al. A phase Ⅰ/Ⅱ trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol, 2012, 14(12):1519-1526.

[1]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞.原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[2]	黎立喜, 张娣, 罗扬, 马飞.PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[3]	肖楠, 孙鹏飞.氧化应激在胶质瘤放化疗敏感性中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 357-361.
[4]	孔春禹, 孙鹏飞.SLC7A11与胶质瘤[J]. 国际肿瘤学杂志, 2022, 49(10): 604-607.
[5]	郭世豪, 任叶青, 郭庚.脑胶质瘤血管生成拟态分子机制[J]. 国际肿瘤学杂志, 2021, 48(6): 362-365.
[6]	王宪伟, 史美燕, 王凤芹, 齐福, 王朝喆, 周飞.TSA上调miR-4298靶向抑制PADI4表达在诱导U251细胞凋亡中的作用[J]. 国际肿瘤学杂志, 2021, 48(4): 193-199.
[7]	张雯, 胡伟国, 宋启斌.3D-ASL与DCE-MRI在脑胶质瘤复发与放射性脑坏死鉴别诊断中的价值[J]. 国际肿瘤学杂志, 2021, 48(10): 631-634.
[8]	赵聪选, 于韬.胶质瘤相关基因的挖掘及预测[J]. 国际肿瘤学杂志, 2020, 47(5): 293-296.
[9]	李开春, 王雅杰.转移性三阴性乳腺癌临床研究现状[J]. 国际肿瘤学杂志, 2020, 47(3): 169-173.
[10]	南阳, 钟跃.长非编码RNA在神经胶质瘤研究中的新进展[J]. 国际肿瘤学杂志, 2020, 47(2): 98-102.
[11]	张雯, 宋启斌, 胡伟国.多模态磁共振成像在脑胶质瘤中的临床应用[J]. 国际肿瘤学杂志, 2020, 47(11): 686-690.
[12]	陈亮, 秦军, 雷军荣, 刘俊, 王璐.miR-1254通过靶向CSF-1抑制胶质瘤细胞的增殖和侵袭能力[J]. 国际肿瘤学杂志, 2020, 47(10): 577-584.
[13]	张千慧, 张洋, 宿伟鹏, 张宋安, 刘攀, 赵化荣.LSD1、MGMT和Ki-67在高级别胶质瘤中的表达及对预后的影响[J]. 国际肿瘤学杂志, 2019, 46(9): 519-525.
[14]	衣琳, 邱实.紫草素抗胶质瘤效应及其作用机制[J]. 国际肿瘤学杂志, 2019, 46(8): 489-491.
[15]	于学娟, 安宏伟, 孙亚梅, 姜政, 张学海, 杨文敬, 张伟. MMP2、TIMP2、Ki-67、P53在胶质瘤组织中的表达及意义[J]. 国际肿瘤学杂志, 2019, 46(12): 718-722.

受体酪氨酸激酶抑制剂在恶性胶质瘤中的临床试验进展

Clinical trials of receptor protein tyrosine kinase inhabitors in malignant glioma

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价